Search Press releases Keywords From To 3 Jun 2026 BIMZELX[®](bimekizumab) data at EULAR 2026 show early and sustained inflammation control can improve patient reported outcomes and limit disease progression in PsA and axSpA Read More 2 Jun 2026 UCB completes acquisition of Neurona Therapeutics, advancing its leadership as innovator in epilepsy through regenerative science Read More 2 Jun 2026 UCB presents research at EUROMIT 2026 highlighting burden of care, need for earlier diagnosis, and impact of pyrimidine nucleoside therapy on people living with TK2d Read More 1 Jun 2026 UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus Read More 19 May 2026 BIMZELX[®](bimekizumab) demonstrates superior efficacy over SKYRIZI[®] (risankizumab) in psoriatic arthritis: BE BOLD Week 16 data Read More 7 May 2026 UCB, Cancer Research UK and Cancer Research Horizons announce new strategic alliance to accelerate development of novel cancer therapies Read More Pagination First page Previous page Previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Page 2 of 65 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
